Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-458.6%
operating margin TTM
-428.26%
revenue TTM
15.43 Million
revenue per share TTM
0.37$
valuation ratios | |
|---|---|
| pe ratio | -0.04 |
| peg ratio | -0.01 |
| price to book ratio | -0.04 |
| price to sales ratio | 0.17 |
| enterprise value multiple | -0.05 |
| price fair value | -0.04 |
profitability ratios | |
|---|---|
| gross profit margin | 90.48% |
| operating profit margin | -428.26% |
| pretax profit margin | -458.6% |
| net profit margin | -458.6% |
| return on assets | -985.18% |
| return on equity | 162.29% |
| return on capital employed | 1170.92% |
liquidity ratios | |
|---|---|
| current ratio | 0.48 |
| quick ratio | 0.48 |
| cash ratio | 0.22 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 19.63 |
| days of payables outstanding | 985.42 |
| cash conversion cycle | -965.79 |
| receivables turnover | 18.60 |
| payables turnover | 0.37 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.34 |
| debt equity ratio | -0.04 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | -0.04 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -21.97 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.89 |
| cash per share | 0.05 |
| operating cash flow per share | -0.89 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -21.97 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -3,111.92 |
Frequently Asked Questions
When was the last time Carisma Therapeutics, Inc. (NASDAQ:CARM) reported earnings?
Carisma Therapeutics, Inc. (CARM) published its most recent earnings results on 12-11-2025.
What is Carisma Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Carisma Therapeutics, Inc. (NASDAQ:CARM)'s trailing twelve months ROE is 162.29%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Carisma Therapeutics, Inc. (CARM) currently has a ROA of -985.18%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CARM's net profit margin stand at?
CARM reported a profit margin of -458.6% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CARM's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 0.48 in the most recent quarter. The quick ratio stood at 0.48, with a Debt/Eq ratio of -0.04.